BioCryst Pharmaceuticals, Inc. BCRX
8.63 USD +0.05 (+0.64%)
Nov 4, 2026, 11:35 AM EST
8.31 Day range 8.86
6.23 52-week range 11.22
- YTD
- +10.58%
- 1 year
- +27.59%
Analyst view
Consensus: buy
Buy
Price target (mean) 20.55 +138.2% upside
Now 8.63
- Target (low)
- 11.00
- Target (mean)
- 20.55
- Target (high)
- 32.00
Ratings (0m) 11 9 buy · 2 hold · 0 sell
- Strong buy2
- Buy7
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.115 | 0.10 – 0.13 | 0.16 | -28.1% | 165.68M | +3.9% | 2 |
| Next quarter | 0.13 | 0.11 – 0.15 | 0.2083 | -37.6% | 169.77M | -58.2% | 2 |
| Current year | 0.75 | 0.70 – 0.80 | 0.6347 | +18.2% | 710.08M | -18.8% | 2 |
| Next year | 0.825 | 0.80 – 0.85 | 0.75 | +10.0% | 736.43M | +3.7% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Sep 10, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Sep 8, 2026 | Needham | Reiterated | Buy | Buy |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 30, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| May 7, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 7, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 6, 2026 | Needham | Maintained | Buy | Buy |
| Jan 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Dec 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 5, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 4, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Nov 4, 2025 | Needham | Maintained | Buy | Buy |
| Oct 15, 2025 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 15, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Oct 15, 2025 | Needham | Maintained | Buy | Buy |
| Aug 4, 2025 | Needham | Maintained | Buy | Buy |
| Jul 1, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jun 30, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 30, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Jun 27, 2025 | Needham | Reiterated | Buy | Buy |
| Jun 25, 2025 | Needham | Reiterated | Buy | Buy |
| May 7, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 6, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| May 6, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| May 6, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 6, 2025 | Needham | Maintained | Buy | Buy |
